Pharmacologic classification: corticosteroid
Therapeutic classification: ocular anti-inflammatory
Pregnancy risk category: C
AVAILABLE FORMS
Ophthalmic emulsion: 0.05%
INDICATIONS AND DOSAGES
Inflammation and pain associated with ocular surgery—
Adults: One drop into the conjunctival sac of the affected eye q.i.d. beginning 24 hours after surgery for 2 weeks. Decrease to b.i.d. for 1 week, and then taper according to the patient's response.
CONTRAINDICATIONS AND CAUTIONS
Contraindicated in patients with ocular tuberculosis, epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, or other fungal or viral diseases of ocular structures.
Use cautiously in patients with glaucoma (any form) because intraocular pressure may increase.
Use cautiously in patients with a history of herpes simplex. Drug may prolong or worsen the condition.
INTERACTIONS
None reported.
ADVERSE REACTIONS
EENT: anterior chamber cells, anterior chamber flare, blepharitis, ciliary and conjunctival hyperemia, conjunctival edema, corneal edema, eye inflammation, eye pain, iritis, photophobia, posterior capsule opacification, punctate keratitis, reduced visual acuity.
Reactions may be common, uncommon, life-threatening,
or COMMON AND LIFE-THREATENING.
|
difluprednate